Please note that we are seeing high patient volumes in the emergency department. Learn more >>.

Know before you go to the ER
Select the search type
  • Site
  • Web

Lung Transplant Referral Process

The evaluation for lung transplantation is an intensive and complex process. In order to facilitate the referral and begin the evaluation process, we request that you complete our Lung Transplant Referral Form and provide us with the requested medical records on your patient, if available. Should you have any questions, please do not hesitate to contact our office at 314.362.5378.

You can also download the Lung Transplant Referral Form if you prefer to fax or mail your patient referral.


In 1988, Barnes-Jewish Hospital became one of the first hospitals in the United States with a program fully dedicated to lung transplantation surgery. Our lung transplant program is one of the world's largest with more than 1,500 adult transplant surgeries performed. Today, Barnes-Jewish and Washington University perform 60-70 lung transplants each year, garnering worldwide recognition.


  • One of the largest and most renowned lung transplant programs in the country
  • One of the first lung transplant programs in the country (1988)
  • More than 1,500 lung transplants performed
  • Exceptional outcomes
  • Specialized and dedicated multidisciplinary team
  • Experienced clinical staff
  • Nationally recognized providers
  • Cutting edge research
  • Comprehensive pulmonary rehab
  • Mentoring and social support programs available to all patients
  • Care provided at one of the top hospitals in the country


Interstitial Lung Disease and Pulmonary Fibrosis

  • Histologic or radiographic evidence of UIP irrespective of vital capacity
  • Histologic evidence of fibrotic NSIP
  • Note: we prefer early referral for these regardless of lung function

Cystic Fibrosis

  • FEV1 below 30% predicted or a rapid decline in FEV1 
  • Exacerbation of pulmonary disease requiring ICU stay.
  • Increasing frequency of exacerbations requiring antibiotic therapy
  • Refractory and/or recurrent pneumothorax.
  • Recurrent hemoptysis not controlled by embolization.

COPD and Alpha-1 Antitrypsin Deficiency Emphysema

  • BODE index exceeding 5
  • FEV1 < 25% of predicted

Pulmonary Arterial Hypertension

  • NYHA functional class III or IV, irrespective of ongoing therapy.
  • Rapidly progressive disease.

Additional General Guidelines

  • Patients must be free from all nicotine product usage for at least 6 months (including e-cigarettes, vapor cigarettes, chew, gum, patches, etc.)
  • Acceptable nutritional status, usually BMI < 35 kg/m2